Diagnosis and treatment of Lupus nephritis: Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish society of internal medicine (SEMI) and the Spanish society of nephrology (S.E.N.)

Nefrologia

Volumn 32, Issue SUPPL. 1, 2012, Pages 1-45

  Ruiz Irastorza, Guillermo ^a   Espinosa, Gerard ^b   Frutos, Miguel A ^c   Jiménez Alonso, Juan ^d   Praga, Manuel ^e   Pallarés, Lucio ^f   Rivera, Francisco ^g   Robles Marhuenda, Ángel ^h   Segarra, Alfons ⁱ   Quereda, Carlos ^j  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g Hospital General   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PRACTICE GUIDELINE;

HUMANS; LUPUS NEPHRITIS;

EID: 84859353763     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Dec.11298     Document Type: Article

References (235)

1. Rivera F, López-Gómez JM, Pérez-García R. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004;66:898-904.
2. Guyatt GH, Oxman AD, Visit GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
3. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;70:2058-65.
4. Quereda C, Barrio V, Gracia López F. Jerarquización del conocimiento científico. El sistema GRADE. Nefrologia Suplemento Extraordinario 2009;29:7-14.
5. Weening JJ, D'Agati VD. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. J Am Soc Nephrol 2004;15:241-50.
6. Grootscholten C, Bajema IM, Florquin S, et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008;23:223-30.
7. Hill GS, Delahousse M, Nochy D, et al. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005;68:2288-97.
8. Schwartz MM, Korbet SM, Lewis EJ, for the Collaborative Study Group. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008;23:1298-306.
9. Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med 2009;133:233-48.
10. Falk RJ, Schur PH, Appel GB. Indications for renal biopsy in patients with lupus nephritis. UpToDate. In: Basow DS (ed.). UpToDate, Waltham, MA, 2011. UpToDate 2011.
11. Rivera F. Biopsia renal. NefroPlus 2009;2:1-8.
12. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens 2005;14:1-8.
13. Daleboudt GM, Bajema IM, Goemaere NN, et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009;24:3712-7.
14. Bajaj S, Albert L, Gladman DD, et al. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 2000;27:2822-6.
15. Hebert LA, Birmingham DJ, Shidham G, et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract 2009;113:c177-c182.
16. Fine DM, Ziegenbein M, Petri M, et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int 2009;76:1284-8.
17. Moroni G, Radice A, Giammarresi G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009;68:234-7.
18. Mok CC. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010;2010:638413.
19. Nachman PH, Glassock RJ. Vascular, Glomerular and Interstitial Diseases. NephSAP 2010;9:150-9.
20. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32.
21. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
22. Beier UH, Green C, Meyers KE. Caring for adolescent renal patients. Kidney Int 2009;77:285-91.
23. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
24. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;365:801-3.
25. Buttgereit F, Straub R, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
26. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
27. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
28. Curtis J, Westfall A, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-6.
29. Gladman D, Urowitz M, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
30. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
31. Thamer M, Hernán MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4.
32. Burgos P, Mcgwin G, Reveille J, et al. Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford) 2010;49:1720-5.
33. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
34. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
35. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
36. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
37. Houssiau F A, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
38. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
39. Yee CS, Gordon C, Dostal C, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2003;63:525-9.
40. Kong KO, Badsha H, Lian TY, et al. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 2004;13:212-3
41. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. An Rheum Dis 2010;69:20-8.
42. Shinjo SK, Bonfa E, Wojdyla D, et al. Grupo Latino Americano de Estudio del Lupus Eritematoso Gladel. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855-62.
43. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
44. Barber CE, Geldenhuys L, Hanly J. Sustained remission of lupus nephritis. Lupus 2006;15:94-101.
45. Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008;17:281-8.
46. Pons-Estel GJ, Alarcon GS, Mcgwin G, et al, LUMINA Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009;61:830-9.
47. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010;62:775-84.
48. Ruggenenti P, Pensa A, Mosconi L, et al. Urinary protein excretion is the best predictor of ESRF in non-diabetic chronic nephropathies. Kidney Int 1998;53:1209-16.
49. Masood S, Jayne D, Karim Y. Beyond immunosuppresionchallenges in the clinical management of lupus nephritis. Lupus 2009;18:106-15.
50. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008;52:475-85.
51. Tse K, Li F, Tang S, Tang CS, et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 2005;14:942-52.
52. Durán-Barragán S, McGwin G Jr, Vila LM, et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decrease risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic UC cohort. Rheumatology (Oxford) 2008;47:1093-96.
53. Afshinnia F, Wilt TJ, Duval S, et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010;25:1173-83.
54. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronaryartery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
55. Mok CC, Poon W L, Lai JPS, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 2010;39:42-9.
56. Faurschou M, Dreyer L, Kamper AL, et al. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62:873-80.
57. Doria A, Schoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-7.
58. Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. J Rheumatol 2010;37:322-9.
59. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockage and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008;155:791-805.
60. Waanders F, Vaidya VS, Van Goor H, et al. Effect of reninangiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009;53:16-25.
61. Gustafsson J, Gunnarsson I, Börjesson O, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009;11:R186.
62. Scalzi LV, Bhatt S, Gilkeson RC, et al. The relationship between race, cigarette smoking and carotid intimal medial thickness in systemic lupus erythematosus. Lupus 2009;18:1289-97.
63. Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153:1089-93.
64. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115-27.
65. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs 2008; 68:925-47.
66. Laksminaranan S, Wals S, Mohanraj, M et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001;28:102-8.
67. Almehed K, Forsblad d'Elia H, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients. Rheumatology 2007;46:1185-90.
68. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515-26.
69. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008;47:920-3.
70. Wu PW, Rhew EY, Dyer AR, et al. 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum 2009;61:1387-95.
71. Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomised trial. Am J Kidney Dis 2009;54:647-52.
72. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004;13:673-8.
73. Mok C, Ying K, Ng W, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:25-33.
74. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-9.
75. Somers E, Marder W, Christman G, et al. Use of a gonadotropinreleasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7.
76. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539-49.
77. Petri MA, Kim MY, Kalunian KC, et al. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-58.
78. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurology 2009;8:998-1005.
79. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
80. O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006;15:778-83.
81. Mekinian A, Queyrel V, Durand-Joly I, et al. PCR Pneumocystis jirovecci positive chez les patients atteints de maladie autoimmune: Pneumocystose pulmonaire ou simple colonisation? Rev Med Int 2010;194-9.
82. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis Lupus 2009;18:257-63.
83. Zabaleta-Lanz ME, Muñoz LE, Tapanes FJ, et al. Further description of early clinically silent lupus nephritis. Lupus 2006;15:845-51.
84. González-Crespo MR, López-Fernández JL, Usera G, et al. Outcome of silent nephritis. Sem Arthritis Rheum 1996;26:468-76.
85. Mok CC, Cheung TT, Lo WH. Minimal mesangial lupus nephritis: a systematic review. Scand J Rheumatol 2010;39:181-9.
86. Lightstone L. Lupus nephritis: where are we now? Curr Op Rheumatol 2010;22:252-6.
87. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of lupus nephritis. Cochrane Database Syst Rev 2004;1:CD002922.
88. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year followup data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4.
89. Zeher M, Doria A, Lan JL, et al. Efficacy and safety of entericcoated mycophenolate sodium (EC-MPS) in combination with two corticosteroids regimens for the treatment of lupus nephritis flare-Results of the MYLUPUS Study. Lupus 2011;20:1484-93.
90. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis Arthritis Res Ther 2006;8:R182.
91. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a metaanalysis of randomized controlled trials. Nephrol Dial Transplant 2007;22:1933-42.
92. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2:968-75.
93. Mak A, Cheak AAC, Tan JYS, et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and metaregression. Rheumatology 2009;48:944-52.
94. Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis. Systematic review and metaanalysis. Medicine 2010;89:227-35.
95. Lee YH, Woo JH, Choi SH, et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010;19:703-10.
96. Mak SK, Lo KY, Lo MW, et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology 2008;13:331-6.
97. Kitiyakara C, Ophascharoensuk V, Changsirikulchai V, et al. Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. Clin Nephrol 2008;69:90-101.
98. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010;49:128-40.
99. Tse KC, Tang CS, Lam MF, et al. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 2009;36:76-81.
100. Wilson ECF, Jayne DRW, Dellow E, et al. The costeffectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 2007;46:1096-101.
101. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis N Engl J Med 2004;350:971-80.
102. Sahin GM, Sahin S, Kiziltas S, et al. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. Renal Fail 2008;30:865-9.
103. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
104. Dooley MA, Jayne D, Ginzler E, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
105. Walsh M, Jayne D, Moist L, et al. Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus 2010;19:628-33.
106. Mok CC, Ying K, Ng W, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:25-33.
107. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006;21:1541-8.
108. Austin HA, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-11.
109. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009;24:15-20.
110. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
111. Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an openlabel trial. Am J Kidney Dis 2004;43:269-76.
112. Tse KC, Lam MF, Tang SC, et al. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007;16:46-51.
113. Szeto CC, Kwan BCH, Lai FMM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology 2008;47:1678-81.
114. Sloan RP, Schwartz MM, Korbet SM, et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative study Group. J Am Soc Nephrol 1996;7:299-305.
115. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
116. Coplon NS, Diskin CJD, Petersen J, et al. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 1983;308:186-90.
117. Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant 2006;21:1749-52.
118. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestationsin a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308.
119. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009;36:63-7.
120. Bastian HM, Roseman JM, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
121. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188-95.
122. Korbet SM, Schwartz MM, Evans J, et al for the Collaborative Study GroupSevere Lupus Nephritis: Racial Differences in Presentation and Outcome. J Am Soc Nephrol 2007;18:244-54.
123. Pasquali S, Banfi G, Zucchelli A, et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993;39:175-82.
124. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol 2009;5:212-20.
125. Mercadal L, Montcels T, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002;17:1771-8.
126. Mok CC, Ying KY, Yim CW, et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 2009;18:1091-5.
127. Austin HAR, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
128. Balow JE, Austin HA, Muenz LR, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-4.
129. Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007;56:924-37.
130. Austin HA 3rd, Boumpas DT, Vaughan EM, et al. High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-8.
131. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerularinjury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59:2156-63.
132. Lim CS, Chin HJ, Jung YC, et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 1999;52:139-47.
133. Al Arfaj AS, Khalil N, Al Saleh S. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol Int 2009;29:1057-67.
134. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005;14:890-5.
135. Ioannidis JPA, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
136. Mok CC, Ho CTK, Chan KW, et al. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-101.
137. Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46-53.
138. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 2004;50:3934-40.
139. Gipson KL, Gipson DS, Massengill SA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: Focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 2009;4:1962-7.
140. Gunnarsson I, Sundelin B, Heimburger M, et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria. J Rheumatol 2002;29:693-9.
141. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999;10:1281-90.
142. Kessler M, Frimat L, Panescu V, et al. Impact of nephrology referral on early and midterm outcomes in ESRD: EPidemiologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): Results of a 2-year, prospective, community-based study. Am J Kidney Dis 2003;42:474-9.
143. Siu YP, Leung KT, Tong MK, et al. Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2005;20:2797-802.
144. Huang JW, Hung KY, Yen CJ, et al. Systemic lupus erythematosus and peritoneal dialysis: outcomes and infectious complications. Perit Dial Int 2001;21:143-7.
145. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
146. Rietveld A, Berden JH. Renal replacement therapy in lupus nephritis. Nephrol Dial Transplant 2008;23:3056-60.
147. Nossent HC, Swaak TJ, Berden JH: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. Am J Med 1990;89:169-74.
148. Bruce IN, Hallett DC, Gladman DD, et al. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol 1999;26:1490-4.
149. Okano K, Yumura W, Nitta K, et al. Analysis of lupus activity inend-stage renal disease treated by hemodialysis. Intern Med 2001; 40:598-602.
150. Krane N, Burjak K, Archie M, et al. Persistent lupus activity in endstage renal disease. Am J Kidney Dis 1999;33:872-9.
151. Lee PT, Fang HC, Chen CL, et al. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus 2003;12:827-32.
152. Goo Ys, Park Hc, Choi Hy, et al. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J 2004;45:199-206.
153. Weng CH, Hsu CW, Yu CC, et al. Dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes. Kidney Blood Press Res 2009;32:451-6.
154. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996;101:100-7.
155. Andrews PA, Warr KJ, Hicks A, et al. Impaired outcome of continuous ambulatory peritoneal dialysis in immunosuppressed patients. Nephrol Dial Transplant 1996;11:1104-8.
156. Bunnapradist S, Chung P, Peng A, et al. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation 2006;82:612-8.
157. Chelamcharla M, Javaid B, Baird BC, et al. The outcome of renal transplantation among systemic lupus erythematosus patients. Nephrol Dial Transplant 2007;22:3623-30.
158. Ponticelli C, Moroni G. Renal transplantation in lupus nephritis. Lupus 2005;14:95-8.
159. Berden JHM. Lupus nephritis. Kidney Int 1997;52:538-58.
160. Stone J, AmendW, Criswell L. Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999;34:1040-7.
161. Ghafari A, Etmadi J, Adrdalan MR. Renal transplantation in patients with lupus nephritis: a single centre experience. Transplant Proc 2008;40:143-4.
162. Quereda C, Pardo A, Lamas S, et al. Lupus-like in vitro anticoagulant activity in end-stage renal disease. Nephron 1988;49:39-44.
163. Marcén R, Pascual J, Quereda C, et al. Lupus anticoagulant and thrombosis of kidney allograft vessels. Transplant Proc 1990;22(4):1396-8.
164. Osman C, Swaak A. Lymphocytotoxic antibodies in SLE: a review of the literature. Clin Rheumatol 1994;13:21-7.
165. Lochhead KM, Pirsch JD, D'Allesandro AM, et al. Risk factors for renal allograft loss in patients with systemic lupus erythematosus. Kidney Int 1996;49:512-7.
166. Clowse MEB, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199:e1-6.
167. Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 2005;32:1709-12.
168. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003;16:161-7.
169. Moroni G, Ponticelli C. Pregnancy after lupus nephritis. Lupus 2005;14:89-94.
170. Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 2009;24:519-25.
171. Day CJ, Lipkin GW, Savage COS. Lupus nephritis and pregnancy in the 21st century. Nephrol Dial Transplant 2009;24:344-7.
172. Smyth A, Oliveira GHM, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:260-8.
173. Huong DL, Wechsler B, Vauthier-Brouzes D, et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 2001;60:599-604.
174. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991;34:1538-45.
175. Ruiz-Irastorza G, Lima F, Alves J, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996;35:133-8.
176. Cortés-Hernández J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology 2002;41:643-50.
177. Rahman FZ, Rahman J, Al-Suleiman SA, et al. Pregnancy outcome in lupus nephropathy. Arch Gynecol Obstet 2005;271:222-6.
178. Moroni G, Quaglini S, Banfi G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis 2002;40:713-20.
179. Kong NCT. Pregnancy of a lupus patient-a challenge to the nephrologist. Nephrol Dial Transplant 2006;21:268-72.
180. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998;7:622-9.
181. Williams D, Davison J. Chronic kidney disease in pregnancy. BMJ 2008;336:211-5.
182. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006;15:148-55.
183. Østensen M, Khamashta M, Lockshin M, et al. Antiinflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209-18.
184. Clowse MEB, Magder L, Witter F, Petri MA. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7.
185. Chakravarty EF, Colón I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.
186. Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. Lupus 1991;1:19-25.
187. Von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355:87-92.
188. Cooper WO, Hernández-Díaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51.
189. Askie LM, Duley L, Henderson-Smart DJ, et al. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791-8.
190. Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004;50:2569-79.
191. Amigo MC. Kidney disease in antiphospholipid syndrome. Rheum Dis Clin North Am 2006;32:509-22.
192. Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36.
193. Alchi B, Griffiths M, Jayne D. What nephrologists need to know about antiphospholipid syndrome. Nephrol Dial Transplant 2010;25:3147-54.
194. Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, et al. Evidencebased recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibodypositive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011;20:206-18.
195. Quereda C, Pardo A, Lamas S, et al. High prevalence of lupus anticoagulant in hemodialysis patients. Life Support Syst 1985;3 S1:58-62.
196. Quereda C, Pardo A, Lamas S, et al. Lupus-like in vitro anticoagulant activity in end-stage renal disease. Nephron 1988;49:39-44.
197. García-Martín F, De Arriba G, Carrascosa T, et al. Anticardiolipin antibodies and lupus anticoagulant in endstage renal disease. Nephrol Dial Transplant 1991;6:543-7.
198. Chew SL, Lins RL, Daelemans R, et al. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant 1992;7:1194-8.
199. Phillips AO, Jones HW, Hambley H, et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients. Nephron 1993;65:350-3.
200. Prieto LN, Suki WN. Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis 1994;23:587-90.
201. Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995;48:794-800.
202. Shafi ST, Gupta M. Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. J Vasc Access 2007;8:103-8.
203. Lee CH, Wang IK, Chen TC, et al. Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: a retrospective study. Int J Clin Pract 2006;60:1591-5.
204. Marcen R, Pascual J, Quereda C, et al. lupus anticoagulant and thrombosis of kidney allograft vessels. Transplant Proc 1990;22:1396-8.
205. Canaud G, Bienaimé F, Noël LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010;10:2051-60.
206. Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004;4:139-49.
207. Vaidya S, Sellers R, Kimball P. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation 2000;69:1348-52.
208. Moroni G, Greloni GC, Ponticelli C. Late recurrence of lupus nephritis after long-term clinical remission. Nephrol Dial Transplant 2001;16:849-52.
209. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
210. Chan TM, Tse KC, Tang CSO, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72.
211. Gibson KL, Gipson DS, Massengill SA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 2009;4:1962-7.
212. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
213. Suría S, Checa MD. Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide. Nefrologia 2007;27:459-65.
214. Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-87.
215. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009;24:2157-60.
216. Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999;34:530-9.
217. Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19: 2001-10.
218. Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006;36:71-81.
219. Rauova L, Lukac J, Levy Y, et al. High-dose intravenous immunoglobulins for lupus nephritis-a salvage immunomodulation. Lupus 2001;10:209-13.
220. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
221. Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (ln): results from the randomized, double-blind phase III LUNAR Study [abstract]. Arthritis Rheum 2009;60:S1149.
222. Vigna-Pérez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 2006;8:R83.
223. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase i/ii doseescalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
224. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and retreatment. Arthritis Rheum 2006;54:2970-82.
225. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458-66.
226. Díaz-Lagares C, Croca S, Shangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimm Rev 2011 [Epub ahead of print].
227. Carroll RP, Brown F, Kerr PG. Anti-cd20 antibody treatment in refractory class iv lupus nephritis. Nephrol Dial Transplant 2007;22:291-3.
228. Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-33.
229. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-4.
230. Matsumura R, Umemiya K, Sugiyama T, et al. Study Group on Nephrology at the National Hospital Organization of Japan. Anti-tumor necrosis factor therapy in patients with difficultto-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009;27:416-21.
231. Ogawa H, Kameda H, Amano K, et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 2010;19:162-9.
232. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol 2009;19:606-15.
233. Uchino A, Tsukamoto H, Nakashima H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol 2010;28:6-12.
234. Cortés-Hernández J, Torres-Salido MT, Segarra Medrano A, et al. Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010;25:3939-48.
235. Yamaji K, Kim YJ, Tsuda H, et al. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroidresistant lupus nephritis. Ther Apher Dial 2008;12:298-305.